Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cocrystal Pharma, Inc. (COCP : NSDQ)

• Company Description    Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $0.38 Daily Weekly Monthly 20 Day Moving Average: 277,826 shares Shares Outstanding: 97.47 (millions) Market Capitalization: $37.04 (millions) Beta: 1.13 52 Week High: $1.49 52 Week Low: $0.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.74% -17.50% 12 Week -30.26% -23.34% Year To Date -41.54% -26.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19805 N. CREEK PARKWAY - BOTHELL,WA 98011 USA ph: 786-459-1831 fax: - jcain@lhai.com http://www.cocrystalpharma.com

• General Corporate Information    Officers Sam Lee - President and Co-Interim Chief Executive Officer Roger Kornberg - Chairman James Martin - Chief Financial Officer and Co-Interim Chief Execu Phillip Frost - Director Steven Rubin - Director Peer Information Cocrystal Pharma, Inc. (CORR.) Cocrystal Pharma, Inc. (RSPI) Cocrystal Pharma, Inc. (CGXP) Cocrystal Pharma, Inc. (BGEN) Cocrystal Pharma, Inc. (GTBP) Cocrystal Pharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19188J300 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 97.47 Most Recent Split Date: (:1) Beta: 1.13 Market Capitalization: $37.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.50 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -19.76 12/31/21 - -19.21 09/30/21 - -17.75 ROA 03/31/22 - -19.28 12/31/21 - -18.71 09/30/21 - -17.25 Current Ratio 03/31/22 - 35.56 12/31/21 - 38.40 09/30/21 - 50.85 Quick Ratio 03/31/22 - 35.56 12/31/21 - 38.40 09/30/21 - 50.85 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -2,351.57 Book Value 03/31/22 - 0.75 12/31/21 - 0.80 09/30/21 - 0.83 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.01 09/30/21 - 0.02

Powered by Zacks Investment Research ©